pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,841 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1784Endpoints1390Fierce Biotech710BioSpace700BioPharma Dive525raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12325Rare Disease3219Immunology2863Cardiology2745Hematology2177Pulmonology2143Vaccines
  • Men less likely to seek suicide help despite higher discussion rates, Crisis Text Line report shows
    The nonprofit Crisis Text Line reviewed 1.5 million text messages it received in 2025 and discovered that fewer than one‑fifth of the users identified as male only. Even though men made up a small…
    STAT · 6mo agoNegative↗ source
  • Alcohol screening often skipped in primary care, raising health costs
    Doctors are expected to ask patients about their alcohol consumption during routine checkups, but many primary care visits omit or rush this conversation. Evidence-based screening tools can be app…
    STAT · 6mo agoNegative↗ source
← prev
page 107 of 114
next →
111
globenewswire health73
fda press59
1796
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
STAT investigates why alcohol remains America’s leading cause of death and calls for Medicaid work requirement exemptions
STAT’s D.C. Diagnosis newsletter examines why alcohol continues to be the United States' deadliest drug, highlighting its persistent impact on public health. The piece references cultural commenta…
STAT · 6mo agoNegative↗ source
  • PCOS renamed PMOS after decade-long scientific effort
    A new name for the condition formerly known as polycystic ovary syndrome (PCOS) has been introduced. The term polyendocrine metabolic ovarian syndrome (PMOS) was presented in a paper published in…
    STAT · 6mo agoPositive↗ source
  • Astellas revisits gene therapy for XLMTM, offering new hope after earlier setbacks
    A gene therapy for the rare muscle disorder X‑linked myotubular myopathy (XLMTM) showed mixed results in early trials, with some boys experiencing dramatic recoveries while others died. Astellas P…
    STAT · 6mo agoPositive↗ source
  • Supreme Court pauses restrictions, keeps abortion pill mifepristone available through pharmacies and mail
    The Supreme Court issued an order that maintains current access to the abortion medication mifepristone while it reviews a case challenging FDA prescribing rules. The order, signed by Justice Samu…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Colombian court upholds compulsory license for HIV drug, affirming legal framework
    The Court of Justice of the Andean Community ruled that Colombia's issuance of a compulsory license for an HIV medicine two years ago was lawful. The tribunal said the government had a valid publi…
    STAT · 6mo agoRegulatoryPositive↗ source
  • Medicare falls short on projected Alzheimer’s drug costs as fewer seniors use Leqembi
    Bob Herman reports that Medicare's earlier estimate that the new Alzheimer's therapy Leqembi would cost the program $3.5 billion in 2025 has proved far too high. The agency's actuaries based the fo…
    STAT · 6mo agoRegulatoryNegative↗ source
  • FDA policy lets some flavored vapes stay on shelves without full approval, raising expert concerns
    The Food and Drug Administration announced a new guidance that allows certain flavored e-cigarettes and nicotine pouches to remain on the market even though they have not received full authorizatio…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Astellas therapy brings new hope to rare disease patients amid broader biotech challenges
    A new Astellas treatment is being highlighted as a source of optimism for a community affected by a rare disease, after a period of setbacks in the program. The article also notes a revived gene t…
    STAT · 6mo agoPositive↗ source
  • Medicare uptake of newly approved Alzheimer’s drugs Leqembi and Kisunla falls short of expectations
    Medicare is seeing much lower use of the two Alzheimer’s treatments that received FDA approval earlier this year. The drugs, Leqembi and Kisunla, were expected to generate notable spending for Med…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Experts call for licensing framework as Utah pauses AI chatbot prescription program
    Alon Bergman, an assistant professor of medical ethics at the University of Pennsylvania, argues that AI-driven medical tools need a licensing system. He points to Utah’s recent pilot with the AI c…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Medicare cuts projected spending on new Alzheimer’s drugs as uptake remains low
    Medicare is spending far less on the recently approved Alzheimer’s treatments Leqembi and Kisunla than officials had anticipated. The Centers for Medicare and Medicaid Services said the agency does…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Providers and insurers vie to influence upcoming No Surprises Act arbitration rule
    The federal government is preparing to release a final rule that will reshape the arbitration process under the No Surprises Act. Health care providers and insurers are both scrambling to have thei…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • President Trump says government may consider approving certain forms of kratom-derived 7-OH
    President Trump suggested the federal government could move to approve some forms of 7-OH, an opioid derived from the kratom plant. 7-OH, short for 7-hydroxymitragynine, occurs naturally in kratom…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • FDA commissioner Marty Makary faces possible dismissal amid political pressure, while new insights link menstrual cycles to mental health
    Theresa Gaffney’s Morning Rounds newsletter highlighted a growing body of research that connects menstrual cycle patterns with fluctuations in mental health, underscoring the importance of gender‑s…
    STAT · 6mo agoNeutral↗ source
  • AI dependence mirrors addiction, warns psychiatrist, sparking debate on hidden costs
    Jonathan Avery, vice chair for addiction psychiatry at Weill Cornell Medicine, reflects on his podcast about addiction and the mixed feedback he receives. In a recent episode he interviewed NYU ne…
    STAT · 6mo agoNeutral↗ source
  • Dermatophilosis identified in clusters of European gay men, a mild livestock skin disease
    Researchers in France and Spain have diagnosed several men who have sex with men with dermatophilosis, a bacterial skin infection normally seen in livestock. The cases occurred without any known c…
    STAT · 6mo agoNeutral↗ source
  • Experts criticize CDC's limited role as hantavirus outbreak spreads on cruise ship
    Health officials are dealing with a hantavirus outbreak affecting passengers on a cruise ship, and the World Health Organization has taken the lead in coordinating the response. The U.S. Centers fo…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Dr. Glaucomflecken urges national focus on medicine’s corporatization in First Opinion podcast
    The First Opinion podcast featured an interview with ophthalmologist and comedian Will Flanary, better known as Dr. Glaucomflecken. He discussed his views on the growing corporatization of medicine…
    STAT · 6mo agoNeutral↗ source
  • Opinion piece questions bioethical basis of RFK Jr’s alleged raccoon penis collection
    An opinion article highlights a claim that Robert F. Kennedy Jr. once removed the penis of a dead raccoon in 2001. The allegation was first reported in a recent biography and cited during a congres…
    STAT · 6mo agoNegative↗ source
  • Roche to acquire PathAI for $750 million to boost AI pathology
    Roche announced it will acquire Boston based PathAI for an upfront payment of $750 million. The acquisition follows a partnership that began in 2021 and is intended to speed the use of artificial i…
    STAT · 6mo agoDealPositive↗ source
  • Former FDA officials and pharma groups weigh in as Supreme Court considers mifepristone regulation
    The Supreme Court is expected to act on a case involving the abortion pill mifepristone after a pause on a federal appeals court order that halted mail‑order distribution. The decision could resha…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Medicare’s new RAPID coverage pathway speeds adult device access, but pediatric devices still lag
    The Centers for Medicare and Medicaid Services and the FDA introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. The new process promises Medicare natio…
    STAT · 6mo agoRegulatoryPositive↗ source
  • Capricor sues Japanese partner over botched Duchenne therapy launch and pricing concerns
    Capricor Therapeutics has filed a lawsuit against its Japanese collaborator Nippon Shinyaku and its subsidiary NS Pharma. The biotech alleges the partners mishandled preparations for the launch of…
    STAT · 6mo agoNegative↗ source